All In Biotech

Drug Trial Radar · NCT01703559

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Double-Masked Parallel Evaluation of the Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Sep 9, 2011

Primary completion

Apr 16, 2012

Study completion Apr 30, 2012

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Oct 10, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objectives of this study are: * To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity * To evaluate the ocular and systemic safety of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) compared to its vehicle, a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate

Conditions

  • Night Vision Complaints
  • Decrease in Night Vision
  • Disturbance; Vision, Loss

Interventions

  • Phentolamine Mesylate Ophthalmic Solution 1.0%Drug

    Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

  • Phentolamine Mesylate Ophthalmic Solution 0.5%Drug

    Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist

  • Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)Other

    Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Eyes With ≥ 0.3 Log Increase in Mesopic Contrast Sensitivities for at Least 2 HACSS FrequenciesTime frame: Postdose Day 1, 4, 8, 15, and Day 15 (LOCF=Last Observation Carried Forward)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Phoenix, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.